Page values for "Adalimumab"

Nav

"Medicines" values

1 row is stored for this page

Field	Field type	Value
generic	`String`	Adalimumab
brand	`String`	Humira; biosimilars Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Yusimry, Abrilada
structure	`File`
classes	List of `String`, delimiter: `,`	[[:Category:TNF_inhibitors\|TNF-α inhibitor]] • [[:Category:Biologics\|Biologic]] • [[:Category:DMARDs\|DMARD]] • [[:Category:Immunosuppressants\|Immunosuppressant]] • [[:Category:Monoclonal_antibodies\|Monoclonal antibody (fully human IgG1)]]
mechanism	`String`	'"`UNIQ--vote-000010F8-QINU`"' Pre-treatment screening for latent TB (PPD or IGRA) and chronic hepatitis B is standard. Anti-drug antibody formation is a recognized cause of secondary loss of response'"`UNIQ--ref-000010F9-QINU`"'.
uses	`String`
starting_dose	`String`	40 mg SC every other week (most adult indications); IBD induction 160 mg week 0, 80 mg week 2, then 40 mg every other week
preparations	`String`	40 mg/0.4 mL or 40 mg/0.8 mL prefilled syringe and autoinjector pen; 10, 20, 80 mg pediatric/induction strengths
fda_max	`String`	40 mg every week (selected indications); otherwise 40 mg every other week
pill_id	`Text`
routes	List of `String`, delimiter: `,`	Subcutaneous
onset	`String`	Symptomatic effect within weeks; full response by 12-24 weeks
duration	`String`	2 weeks per dose
halflife	`String`	~14 days'"`UNIQ--ref-00001103-QINU`"'
bioavailability	`String`	~64% from SC depot'"`UNIQ--ref-00001104-QINU`"'
pregnancy	`String`
legal	`String`